Axitinib

CHF 54.00
In stock
SYN-1014-M0011 mgCHF 54.00
SYN-1014-M0055 mgCHF 66.00
SYN-1014-M01010 mgCHF 78.00
SYN-1014-M05050 mgCHF 84.00
SYN-1014-M100100 mgCHF 144.00
 
More Information
Product Details
Synonyms AG-013736
Product Type Chemical
Properties
Formula C22H18N4OS
MW 386.5
CAS 319460-85-0
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key RITAVMQDGBJQJZ-FMIVXFBMSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated. The IC(50) numbers reported for Axitinib are sub to low nanomolar in range.
Product References
  1. Sunitinib: from rational design to clinical efficacy: L.Q. Chow & S.G. Eckhardt; J. Clin. Oncol. 25, 884 (2007)
  2. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors: K. Lee, et al.; Eur. J. Med. Chem. 45, 5420 (2010)
  3. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents: R. Laufer, et al.; J. Med. Chem. 56, 6069 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.